Observational studyScientific reports2026

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study.

Charlène Lefèvre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.